Dow Jones
38 460,92 -42,77 (-0,11 %) Nasdaq
15 712,75 +16,11 (+0,10 %) Nikkei 225
37 672,69 -787,39 (-2,05 %) EUR/USD
1,0708 +0,0007 (+0,06 %) HANG SENG
17 281,67 +80,40 (+0,47 %) Bitcoin EUR
59 951,43 -2 293,18 (-3,68 %)
Editas Medicine, Inc. (EDIT)
Échanges après Bourse :
Editas Medicine, Inc.
11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 265
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Gilmore O'Neill M.D. | President, CEO & Director | 1,04M | S.O. | 1964 |
| Mr. Erick J. Lucera C.F.A., CPA | CFO & Executive VP | 911,46k | S.O. | 1968 |
| Dr. Linda C. Burkly Ph.D. | Executive VP & Chief Scientific Officer | 522,44k | S.O. | 1957 |
| Dr. Baisong Mei M.D., Ph.D. | Executive VP & Chief Medical Officer | 654,9k | S.O. | 1964 |
| Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member | S.O. | S.O. | S.O. |
| Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member | S.O. | S.O. | 1954 |
| Cristi Barnett | Corporate Communications & Investor Relations | S.O. | S.O. | S.O. |
| Ms. Charlene Stern J.D., Ph.D. | Executive VP & General Counsel | S.O. | S.O. | S.O. |
| Ms. Linea Aspesi | Executive VP & Chief People Officer | S.O. | S.O. | 1970 |
| Ms. Caren Deardorf | Executive VP and Chief Commercial & Strategy Officer | S.O. | S.O. | 1966 |
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Editas Medicine, Inc. en date du 1 avril 2024 est 6. Les scores principaux sont Audit : 2; Société : 4; Droits des actionnaires : 8; Compensation : 9.
